Proleukin is a recombinant IL-2 traditionally used at high doses for cancer therapy that has recently been used with remarkable success at lower doses in graft-versus-host disease (GVHD) and hepatitis C-induced vasculitis with therapeutic responses correlating with increased Treg frequencies [20,21]. This evidence concerns the gene IL2 and graft versus host disease.